Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 14/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27354928 | 0.94 | ELANE (0.41) | ELANEOPRM1OPRD1OGFRL1IRAK4 | |
| SCHEMBL20689276 | 0.91 | ELANE (0.42) | ELANETYK2 | |
| SCHEMBL20689650 | 0.85 | TYK2 (0.43) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL20689226 | 0.85 | TYK2 (0.43) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL21948215 | 0.83 | TYK2 (0.46) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL21960630 | 0.83 | TYK2 (0.46) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL21246072 | 0.83 | OPRM1 (0.45) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL20689215 | 0.83 | TYK2 (0.44) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL20689506 | 0.83 | TYK2 (0.44) | ELANEOPRM1OPRD1OGFRL1TYK2 | |
| SCHEMBL31245702 | 0.83 | ELANE (0.38) | ELANEOPRM1OPRD1OGFRL1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | ELANE 3701/4885OPRM1 1769/4885OPRD1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.